140 related articles for article (PubMed ID: 24434399)
1. Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient.
Sivakumar V; Sriramnaveen P; Krishna C; Manjusha Y; Reddy YS; Sridhar N; Subramanian S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):149-51. PubMed ID: 24434399
[No Abstract] [Full Text] [Related]
2. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients.
Dick TB; Raines AA; Stinson JB; Collingridge DS; Harmston GE
Transplant Proc; 2011 Sep; 43(7):2664-8. PubMed ID: 21911143
[TBL] [Abstract][Full Text] [Related]
3. Fludrocortisone Is an Effective Treatment for Hyperkalaemic Metabolic Acidosis in Kidney Transplant Recipients on Tacrolimus: A Case Series.
Gama RM; Makanjuola D; Wahba M; Quan V; Phanish M
Nephron; 2022; 146(2):190-196. PubMed ID: 34784594
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.
Heering PJ; Kurschat C; Vo DT; Klein-Vehne N; Fehsel K; Ivens K
Clin Transplant; 2004 Apr; 18(2):186-92. PubMed ID: 15016134
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases.
Pavleska-Kuzmanovska S; Popov Z; Ivanovski O; Ristovska V; Masin-Spasovska J; Rambabova-Busljetic I; Ivanovski N
Exp Clin Transplant; 2014 Oct; 12(5):479-83. PubMed ID: 24417207
[TBL] [Abstract][Full Text] [Related]
6. The Case | Severe hypertension and hyperkalemia in a kidney transplant recipient.
Dupont V; Colosio C; Hureaux M; Mokri L; Schvartz B; Vuiblet V; Braconnier A; Vargas-Poussou R; Rieu P
Kidney Int; 2019 Aug; 96(2):529-530. PubMed ID: 31331484
[No Abstract] [Full Text] [Related]
7. Type 4 renal tubular acidosis in a kidney transplant recipient.
Kulkarni M
Biomed J; 2016 Feb; 39(1):85-6. PubMed ID: 27105603
[TBL] [Abstract][Full Text] [Related]
8. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities.
Higgins R; Ramaiyan K; Dasgupta T; Kanji H; Fletcher S; Lam F; Kashi H
Nephrol Dial Transplant; 2004 Feb; 19(2):444-50. PubMed ID: 14736972
[TBL] [Abstract][Full Text] [Related]
9. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: case report.
Riveiro-Barciela M; Campos-Varela I; Tovar JL; Vargas V; Simón-Talero M; Ventura-Cots M; Crespo M; Bilbao I; Castells L
Transplant Proc; 2011 Dec; 43(10):4016-8. PubMed ID: 22172892
[TBL] [Abstract][Full Text] [Related]
10. Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Mactier RA; Khanna R
South Med J; 1988 Jun; 81(6):799-801. PubMed ID: 3375885
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients.
Rattanavich R; Malone AF; Alhamad T
Transpl Int; 2019 Jan; 32(1):110-111. PubMed ID: 30444015
[No Abstract] [Full Text] [Related]
12. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients.
Furth S; Neu A; Colombani P; Plotnick L; Turner ME; Fivush B
Pediatr Nephrol; 1996 Feb; 10(1):64-6. PubMed ID: 8611359
[TBL] [Abstract][Full Text] [Related]
13. Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation.
Jones JW; Gruessner RW; Gores PF; Matas AJ
Transplantation; 1993 Oct; 56(4):1013-5. PubMed ID: 8212180
[No Abstract] [Full Text] [Related]
14. Alopecia as a consequence of tacrolimus therapy in renal transplantation?
Talbot D; Rix D; Abusin K; Mirza D; Manas D
Transplantation; 1997 Dec; 64(11):1631-2. PubMed ID: 9415574
[No Abstract] [Full Text] [Related]
15. Tacrolimus-associated mania with psychotic symptoms in a child after renal transplant.
Gupta P; Singh J; Mahapatra A; Sharan P
Natl Med J India; 2018; 31(5):281-282. PubMed ID: 31267993
[TBL] [Abstract][Full Text] [Related]
16. Severe symptomatic hyponatremia--an uncommon presentation of tacrolimus nephrotoxicity.
Bagchi S; Husain Zaidi S; Prasad Mathur R
Nephrol Dial Transplant; 2011 Jun; 26(6):2042-4. PubMed ID: 21454354
[TBL] [Abstract][Full Text] [Related]
17. Anorexia nervosa in a pediatric renal transplant recipient and its reversal with cyclosporine.
Okechuku G; Boulos AK; Herman L; Upadhyay K
Pediatr Transplant; 2015 May; 19(3):E78-82. PubMed ID: 25661468
[TBL] [Abstract][Full Text] [Related]
18. Fludrocortisone Among Adult Renal Transplant Recipients With Persistent Hyperkalemia: Single-Center Experience.
Gheith OA; Dahab M; Nagib AM; Adel M; Elserwy N; Sobhy I; AbdelMonem M; Abo Atya H; Al-Otaibi T
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):69-73. PubMed ID: 35384810
[TBL] [Abstract][Full Text] [Related]
19. Control of hyperkalemia with fludrocortisone in a patient with systemic lupus erythematosus.
Dreyling KW; Wanner C; Schollmeyer P
Clin Nephrol; 1990 Apr; 33(4):179-83. PubMed ID: 2350905
[TBL] [Abstract][Full Text] [Related]
20. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
Kamel KS; Ethier JH; Quaggin S; Levin A; Albert S; Carlisle EJ; Halperin ML
J Am Soc Nephrol; 1992 Feb; 2(8):1279-84. PubMed ID: 1627752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
